Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NASDAQ: CRBP · Real-Time Price · USD
9.82
-0.26 (-2.58%)
At close: Apr 28, 2026, 4:00 PM EDT
10.20
+0.38 (3.87%)
Pre-market: Apr 29, 2026, 8:00 AM EDT
CRBP Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
36
Market Cap
174.17M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Black Diamond Therapeutics | 70.00M |
| Protalix BioTherapeutics | 52.74M |
| Precision BioSciences | 34.26M |
| Tonix Pharmaceuticals Holding | 13.11M |
| Korro Bio | 6.39M |
| Cartesian Therapeutics | 2.80M |
| Humacyte | 2.04M |
CRBP News
- 21 days ago - Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge - Benzinga
- 7 weeks ago - Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 2 months ago - Corbus Pharmaceuticals Holdings Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference - Transcripts
- 2 months ago - Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference - GlobeNewsWire
- 3 months ago - Corbus Pharmaceuticals Holdings Transcript: 44th Annual J.P. Morgan Healthcare Conference - Transcripts
- 4 months ago - Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 months ago - Corbus Pharmaceuticals Holdings Transcript: Study Update - Transcripts
- 4 months ago - Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss - GlobeNewsWire